Document Detail


FDA's recommendations on the use of long-acting {beta}2 agonists in the management of asthma.
MedLine Citation:
PMID:  20841520     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The revised labeling for long-acting β(2) agonists (LABAs) by the Food and Drug Administration (FDA) is controversial and in part is inconsistent with the 2007 National Asthma Education and Prevention Program asthma guidelines. Two large randomized controlled studies, the Serevent Nationwide Surveillance (SNS) study and the Salmeterol Multicenter Asthma Research Trial (SMART), and a 2008 meta-analysis conducted by the FDA were the main sources of information used to determine the label changes. A paucity of large, well-designed, controlled, prospective studies evaluating the asthma-related risks associated with LABAs makes it difficult to reach a consensus regarding how best to use LABAs in patients with asthma.
Authors:
Christie A Robinson
Publication Detail:
Type:  Journal Article     Date:  2010-09-14
Journal Detail:
Title:  The Annals of pharmacotherapy     Volume:  44     ISSN:  1542-6270     ISO Abbreviation:  Ann Pharmacother     Publication Date:  2010 Oct 
Date Detail:
Created Date:  2010-09-23     Completed Date:  2011-01-13     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9203131     Medline TA:  Ann Pharmacother     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1651-4     Citation Subset:  IM    
Affiliation:
Department of Clinical Pharmacy, University of California San Francisco, USA. robinsonc@pharmacy.ucsf.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adrenergic beta-Agonists / adverse effects,  therapeutic use*
Anti-Asthmatic Agents / adverse effects,  therapeutic use*
Asthma / drug therapy*
Delayed-Action Preparations
Drug Labeling / legislation & jurisprudence
Humans
Meta-Analysis as Topic
Multicenter Studies as Topic
Practice Guidelines as Topic
Randomized Controlled Trials as Topic
United States
United States Food and Drug Administration
Chemical
Reg. No./Substance:
0/Adrenergic beta-Agonists; 0/Anti-Asthmatic Agents; 0/Delayed-Action Preparations

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Acute generalized exanthematous pustulosis as a manifestation of anticonvulsant hypersensitivity syn...
Next Document:  Stress ulcer prophylaxis: reducing non-indicated prescribing after hospital discharge.